NVAX — Novavax, Inc.

Summary of Novavax Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $140 million, a 79% decrease year-over-year, largely due to the absence of noncash revenue recognition from the prior year’s Nuvaxovid APA agreement.
• Nuvaxovid Sales: $10 million primarily from sales in Germany, reflecting the transition of commercial activities to Sanofi.
• Partner-Related Revenue: Supply sales increased by 139% to $33 million, while licensing royalties and other revenues rose by 116% to $97 million, indicating strong progress in the new business model.
• Expenses: Combined R&D and SG&A expenses decreased by 23% on a non-GAAP basis, with R&D down 13% and SG&A down 40%.
• Net Loss: Reported a small net loss of $9 million for the quarter.
• Cash Position: Ended the quarter with $818 million in cash and accounts receivables, with a cash runway projected into 2028.

2. Strategic Updates and Business Highlights

• Partnerships: Novavax is focusing on leveraging its Matrix-M technology through partnerships with major pharmaceutical companies, including Sanofi and Pfizer, which could generate billions in revenue from milestone and royalty opportunities.
• New Collaborations: Signed multiple new Material Transfer Agreements (MTAs) and expanded existing partnerships, targeting over 30 unique indications in infectious diseases and oncology.
• C. difficile Vaccine: Prioritized the C. diff vaccine candidate for clinical advancement, aiming for a 2027 clinic entry, citing significant unmet need and potential market size.
• R&D Leadership: Bob Walker appointed as Head of R&D, focusing on enhancing partner pipelines and advancing Novavax's own assets.

3. Forward Guidance and Outlook

• 2026 Revenue Framework: Reiterated guidance of $230 million to $270 million in adjusted total revenues, with a midpoint expectation of $250 million.
• Expense Guidance: Anticipates combined R&D and SG&A expenses of $310 million to $340 million on a non-GAAP basis for 2026, with a core spend profile of approximately $200 million.
• Path to Profitability: Targeting non-GAAP profitability by 2028, contingent on successful development and commercialization of partnered programs.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The significant drop in total revenue compared to the previous year raises concerns about the sustainability of revenue streams without the prior year's noncash items.
• Market Competition: Increased competition in the vaccine market, particularly with new entrants like Moderna, poses risks to Novavax's market share and revenue potential.
• Execution Risks: Dependence on partners for successful clinical outcomes and commercialization could impact Novavax’s financial performance if partners do not meet milestones or face delays.

5. Notable Q&A Insights

• MTA to License Transition: The conversion from MTAs to formal licensing agreements is dependent on partner success in preclinical testing, with potential timelines of 4 to 6 months for successful partners to move into clinical trials.
• C. diff Vaccine Confidence: The focus on mucosal immunity in the C. diff vaccine candidate is seen as a key differentiator, with preclinical data supporting this approach.
• Combination Vaccine Market: Novavax remains optimistic about the combination vaccine market, particularly with Sanofi's efforts in developing combination products that include Nuvaxovid.
• Strategic Focus: The company is committed to maintaining a lean operating model while enhancing R&D capabilities, reflecting a strategic shift from a singular focus on COVID-19 to a broader infectious disease and oncology portfolio.

This summary encapsulates the key elements of Novavax's Q1 2026 earnings call, highlighting both progress and challenges as the company navigates its strategic transformation.